Abstract Library

#3989 Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K/AKT/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms

Introduction: Pancreatic neuroendocrine neoplasms (pNENs) are relatively rare. Hypoxia and lipid metabolism-related gene acetyl-CoA synthetase 2 (ACSS2) is involved in tumor progression, but its role in pNENs is not revealed.

Conference:

Presenting Author:

Authors: Gu D, Ye M, Zhu G, Bai J, Tang Q,

Keywords: hypoxia, ACSS2, lipid metabolism reprogramming, HMGCS1, PI3K/AKT/mTOR pathway, pancreatic neuroendocrine neoplasm,

#3504 Telotristat ethyl affects crosstalk between tumor cells and stromal fibroblasts in small intestinal neuroendocrine tumors (SI-NETs)

Introduction: SI-NETs are often associated with mesenteric fibrosis (MF) which causes significant morbidity and mortality. Telotristat ethyl (TE) was developed to treat carcinoid syndrome in SI-NET patients however, recent studies indicated TE could also have anti-tumor activity, the mechanism for which remains unclear.

Conference:

Presenting Author:

Authors: Hodgetts H, Martins M, Chen L, Laskaratos F, Hall A,

Keywords: fibrosis, fibroblast, crosstalk, telotristat, intestine, small, tumor,

#3251 Impact of Wnt signalling on CXCR4 expression and function

Introduction: Loss of Somatostatin Receptor 2 (SSTR2) expression and rising Chemokine Receptor Type 4 (CXCR4) expression are associated with increasing dedifferentiation in Neuroendocrine Tumors (NET). CXCR4 expression is associated with enhanced metastatic and invasive potential and worse prognosis in NET, but might be a theranostic target in NET not sufficiently expressing SSTR2. Likewise, aberrant activation of Wnt/β-catenin signalling may promote a more aggressive phenotype in NET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Rogoll D, Mayer L, Meining A, Kudlich T,

Keywords: neuroendocrine, NET, CXCR4, Wnt, Wnt Signalling, beta-catenin, BON-1, QGP-1,

#3242 Establishment and characterization of a new neuroendocrine carcinoma cell model

Introduction: The development of treatment strategies for neuroendocrine carcinomas (NEC) requires in vitro models expressing NEC–specific targets. The CXC Chemokine Receptor Type 4 (CXCR4), that is expressed in NEC with decreasing differentiation, as well as factors involved in chemotherapy resistance may represent such targets.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Weich A

Authors: Weich A, Schreiner J, Rogoll D, Werner R, Meining A,

Keywords: neuroendocrine, net, CXCR4, Wnt signalling, beta-catenin, BON-1, QGP-1,

#3224 MicroRNAs - 193 and -223 alter NET differentiation markers and shape inflammatory response in vitro

Introduction: Future improvements in NETs therapy depend on treatments tailored to tumor cell characteristics, microenvironment and inflammatory status. We recently reported selective downregulation of microRNAs (miRs) -29 and -223 in serum of NET patients, suggesting a possible role in NET disease.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Geisler L, Özdirik B, Mohr R, Knorr J, Tacke F,

Keywords: miR, NET, BON, in vitro, biomarker, inflammation,